Medivo Abstracts Selected for Publication by the American Society of Clinical Oncology

Studies in Pancreatic Cancer and Chronic Myelogenous Leukemia (CML) highlight the important role of lab testing in getting the right treatments to patients.

New York, NY (PRWEB) June 05, 2015 -- Medivo, Inc., a leader in lab data analytics, had two abstracts selected for publication in conjunction with the 2015 ASCO Annual Meeting, which took place from May 29 - June 2, 2015 in Chicago, IL.

In the first abstract, entitled “Association of BCR-ABL mutation testing in patients with CML with likelihood of improvement in subsequent BCR-ABL test results,” Medivo looked at 40,000 CML patients who were tested for BCR-ABL between 2011- 2014, and identified 6,247 instances where CML patients demonstrated a positive (+) slope in test values (using a + slope as a proxy for poor treatment response), yet only 3% of these patients were tested for BCR-ABL mutation soon after showing poor treatment response. Mutation testing was associated with a 52% higher likelihood of patient showing subsequent improvement in BCR-ABL test results, a statistically significant result. These findings support the important role of mutation testing in patients with CML showing poor response to treatment, providing evidence that mutation testing is associated with subsequent improvement in BCR-ABL test results view the full abstract.

In the second abstract, entitled “CA 19-9 and alkaline phosphatase (ALP) as potential biomarkers for pancreatic cancer risk: Analysis from a large lab test database,” Medivo looked at 9,335 patients tested for Carbohydrate Antigen (CA) 19-9 between Jan 2010 and Oct 2014, of whom 1,674 had a confirmed diagnosis of pancreatic cancer. The results support that high levels of both CA 19-9 and ALP may indicate a need for follow-up radiological screening for a pancreatic tumor view the full abstract.

The Medivo Medical Affairs and Data Science teams, consisting of Carol Smyth, Jason M. Bhan, Ajitpal Singh Dhaliwal, Tatiana Sorokina, Niyati Parikh, and Mauricio Alarcon, co-authored these studies along with Jason S. Levitz, hematology and oncology private practice, Far Hills, NJ (both abstracts) and Jerald P. Radich; Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA (CML abstract only).

According to Jason Bhan, MD, Chief Medical Officer and Medivo Co-Founder, the abstracts published at ASCO provide further evidence that “lab tests play a critical role in the diagnosis and monitoring of disease. Understanding how testing impacts care will help ensure that the medical community is more regularly ordering the right test at the right time.”

About Medivo
Medivo is a health data analytics company that unlocks the power of lab data to improve health. Medivo is the largest source of lab data in the U.S., with access to over 150M patients through its nationwide network of partner labs. Medivo analyzes large, de-identified data sets and shares its findings with the medical community at large, as well as with its life science, payer and lab partners, to ensure that appropriate available treatments are provided to patients sooner. Founded in 2010, Medivo’s investors include Safeguard Sciences, Inc. (NYSE:SFE) and Merck Global Health Innovation Fund (GHIF). For more information, visit http://www.medivo.com.
Contact Information
Allison Keeley
Medivo
http://www.medivo.com
+1 (917) 945-8502

Online Web 2.0 Version
You can read the online version of this press release here.